1 HOUR CYP2C19 GENOTYPING
FDA 510(k)-Cleared and CE Marked
Rapid CYP2C19 Genotyping can aid in the implementation of genotype-guided dual antiplatelet therapy (DAPT)1
Rapid CYP2C19 Genotyping can aid in the implementation of genotype-guided dual antiplatelet therapy (DAPT)1
U.S. AHA/ASA guidelines2 recommend dual antiplatelet therapy (DAPT) within 12-24 hours of first stroke or TIA to prevent recurrent stroke for minor stroke or high-risk TIA. Clinical Pharmacogenetic Implementation Consortium (CPIC) guidelines recommend ticagrelor in place of clopidogrel in minor stroke/high-risk TIA patients carrying a CYP2C19 loss of function allele1. The June 2024 AHA Scientific Statement recommends CYP2C19 genetic testing for ACS and PCI patients to decrease the risk of ischemic events while reducing bleeding risks associated with ticagrelor and prasugrel treatments.3
The Genomadix Cube System Tests for...
CYP2C19
looking for a customized solution for your organization?
Click Here APOE
looking for a customized solution for your organization?
Click Here Legionella
looking for a customized solution for your organization?
Click Here Looking For A Customized Solution For Your Organization?
Genomadix Inc. Announces Know-How License Agreement With Mayo Clinic
Genomadix Inc. Announces Know-How License Agreement with Mayo Clinic OTTAWA, ON, Aug. 29, 2022 /CNW/ – Genomadix today announced it has entered
GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM
GENOMADIX ANNOUNCES FDA CLEARANCE TO MARKET THE GENOMADIX CUBE CYP2C19 SYSTEM (OTTAWA, March 22, 2023) Genomadix , based in Ottawa,
Assets of Spartan Bioscience Inc. To Be Acquired By Casa-Dea Finance Limited
GENOMADIX ANNOUNCES SECURING TWO YEARS OF FUNDING Spartan Bioscience Inc. (Spartan) announces today that its primary assets will be acquired
Stanford Adds CYP2C19 Rapid Test to Genomics Menu, Plans Future PGx Expansion
Stanford Adds CYP2C19 Rapid Test to Genomics Menu, Plans Future PGx Expansion Stanford Medical Center has just introduced the Genomadix
- Kleindorfer DO, et al. Stroke. 2021;52:e364–e467 | 2. Pan Y, et al. JAMA Neurol. 2022;79(8):739–745
- Lee et al., Clin Pharmacol Ther. 2022 November ; 112(5): 959–967. doi:10.1002/cpt.2526 |
- Kleindorfer DO, et al. Stroke. 2021;52:e364–e467.
- Pereira et al. Circulation. 2024;150:e129-e150. DOI: 10.1161/CIR.0000000000001257.